Evidence on equilibrative nucleoside transporter 1 (ENT1) and microRNA-21 (miR‐21) is not yet sufficiently convincing to consider them as prognostic biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene SLC29A1 and pancreatic ductal adenocarcinoma.